Healthscope

Healthscope is an Australian private healthcare company headquartered on St Kilda Road in Melbourne. Its principal business has been the ownership and operation of private hospitals, supplemented at various points by pathology, medical-centre, mental-health, rehabilitation and disability-support activities. The company developed into one of Australia's largest private hospital operators, with a nationwide network covering acute care, psychiatric treatment and rehabilitation services. The Healthscope Group was formed in 1985 and entered the Australian Securities Exchange in 1994. Its public-company history was interrupted in 2010, when a consortium advised and managed by TPG Capital and The Carlyle Group acquired the business and took it private. After several years under private ownership, Healthscope returned to the ASX on 28 July 2014. The company subsequently simplified its portfolio by selling its Australian pathology division to Crescent Capital Partners in 2015 and its medical-centre portfolio to Singapore-based Fullerton Healthcare in 2017. Its New Zealand pathology business was sold to NZ Super in 2020. In June 2019, Brookfield Business Partners completed an acquisition of Healthscope, working with institutional investors including the Caisse de dépôt et placement du Québec. The transaction resulted in another delisting. Under Brookfield ownership, Healthscope remained focused primarily on hospital operations, including a substantial mental-health and rehabilitation platform. Its facilities provided treatment for acute medical and surgical needs, psychiatric conditions, substance-use disorders, acquired brain injuries and other rehabilitation requirements. Healthscope Independence Services also offered accommodation, attendant care, transitional support, respite and in-home services for people with disabilities or complex care needs. The company entered a severe financial crisis in 2025. On 26 May 2025, lenders placed Healthscope into receivership after withdrawing support for Brookfield amid reported debt of approximately A$1.6 billion. McGrathNicol was appointed receiver and manager, while KordaMentha was appointed administrator. Commonwealth Bank provided a further A$100 million during the receivership to support continued operations. Public statements and reporting indicated that hospitals were expected to continue operating while the ownership and financing structure were dealt with, although the company’s long-term ownership and organisational form became uncertain. Healthscope’s significance lies in its role as a large private provider within Australia's mixed public-private healthcare system. Its hospital network has included general hospitals as well as specialist psychiatric and rehabilitation facilities. The 2025 receivership placed the future of those assets under review and intensified debate about private-equity ownership, hospital financing, continuity of care and the possible public operation of individual facilities.

Healthscope traces its origins to 1985, when the Healthscope Group was established as a private healthcare business in Australia. It built a presence in the country's private healthcare sector through hospitals and related medical services, eventually developing a broad portfolio that included acute hospitals, psychiatric facilities, rehabilitation centres, pathology laboratories and medical centres. The company became publicly traded on the Australian Securities Exchange in 1994. Its initial public-market period provided capital for expansion in a private healthcare market that operated alongside Australia's public hospital system. Healthscope's activities extended beyond conventional medical and surgical care. The group became a significant operator of private inpatient mental-health facilities and developed rehabilitation services for patients recovering from injury, illness or surgery. In October 2010, a consortium advised and managed by TPG Capital and The Carlyle Group acquired Healthscope. The transaction took the business private and ended its first period as an ASX-listed company. Under private ownership, Healthscope pursued growth in hospital and specialist-care operations. It returned to the public market on 28 July 2014, and its shares were included in the S&P/ASX 200 Index under the code HSO. Following the relisting, Healthscope sold several non-core or separately managed businesses. In July 2015, Crescent Capital Partners acquired the company's Australian Pathology division. In August 2017, Fullerton Healthcare acquired the medical-centre portfolio, comprising a large network of general-practice and specialist clinics. Healthscope later sold its New Zealand pathology business to NZ Super in August 2020. These transactions left hospitals and specialist hospital services as the central focus of the group. Healthscope was acquired by Brookfield Business Partners in 2019. Brookfield announced completion on 6 June 2019, working with institutional investors including the Caisse de dépôt et placement du Québec, which retained a minority interest. The acquisition caused Healthscope to be delisted from the ASX for a second time. During this period, the company operated a substantial Australian hospital network, reported as comprising approximately 40 hospitals, including 12 mental-health facilities and six rehabilitation hospitals. It also operated or managed disability-support and accommodation services through Healthscope Independence Services. Its hospital offering covered general private hospital care, surgery, medical treatment, psychiatric inpatient programs and rehabilitation. Mental-health programs addressed conditions including mood and anxiety disorders, eating disorders, addiction, post-traumatic stress disorder, personality disorders, psychosis, obsessive-compulsive disorder and postnatal depression. Some facilities also offered transcranial magnetic stimulation for depression. Rehabilitation services supported patients with physical recovery needs, neurological conditions and other complex care requirements. Healthscope entered a major financial and ownership crisis in 2025. On 26 May, lenders placed the company into receivership after deciding to withdraw support for Brookfield-owned operations. Reporting placed the company’s debt at about A$1.6 billion. McGrathNicol was appointed receiver and manager, and KordaMentha was appointed administrator. Commonwealth Bank supplied an additional A$100 million to help maintain continuity while the hospitals continued operating. The receivership shifted attention from expansion to asset preservation, operational continuity and the future ownership of the hospital network. It also prompted public discussion about the suitability of private-equity ownership in essential healthcare services and whether some facilities should return to public control. As a result of the receivership, Healthscope's future corporate status, ownership and final asset configuration became uncertain. The brand nevertheless remains associated with a major Australian private hospital network and with specialist mental-health, rehabilitation and disability-support services.

• 2025

  Placed into receivership

  [1]Healthscopeen.wikipedia.org

  Lenders placed Healthscope into receivership amid reported debt of approximately A$1.6 billion.

• 2020

  New Zealand pathology business sold

  [1]Healthscopeen.wikipedia.org

  Healthscope sold its New Zealand pathology business to NZ Super.

• 2019

  Brookfield takeover completed

  [1]Healthscopeen.wikipedia.org

  Brookfield Business Partners completed its acquisition of Healthscope, which was then delisted.

• 2017

  Medical-centre portfolio divested

  [1]Healthscopeen.wikipedia.org

  Fullerton Healthcare acquired Healthscope's medical-centre portfolio and associated specialist clinics.

• 2015

  Australian Pathology divested

  [1]Healthscopeen.wikipedia.org

  Crescent Capital Partners acquired Healthscope's Australian Pathology division.

• 2014

  Relisted on the ASX

  [1]Healthscopeen.wikipedia.org

  Healthscope returned to the Australian Securities Exchange on 28 July 2014.

• 2010

  Taken private by TPG and Carlyle-backed consortium

  [1]Healthscopeen.wikipedia.org

  A consortium advised and managed by TPG Capital and The Carlyle Group acquired Healthscope, leading to its delisting.

• 1994

  Initial ASX listing

  [1]Healthscopeen.wikipedia.org

  Healthscope became publicly listed on the Australian Securities Exchange.

• 1985

  Healthscope Group formed

  [1]Healthscopeen.wikipedia.org

  The Healthscope Group was established as an Australian private healthcare business.

A large, nationwide private hospital and specialist-care operator serving acute, psychiatric, rehabilitation and disability-support needs.

• Acute hospital care

  Private hospitals

  Healthscope's core business has been a nationwide network of private hospitals offering medical, surgical and related inpatient and outpatient services. The network has included facilities in multiple Australian states and territories, serving privately insured and self-funded patients and working within Australia's broader public-private healthcare system.

• Psychiatric care

  Mental-health hospitals and programs

  Healthscope has been one of Australia's largest private operators of inpatient mental-health facilities. Its programs have addressed mood and anxiety disorders, eating disorders, addiction, post-traumatic stress disorder, personality disorders, psychosis, obsessive-compulsive disorder and postnatal depression, with some facilities offering specialised depression treatments.

• Hospital rehabilitation

  Rehabilitation services

  The rehabilitation portfolio has supported recovery following illness, injury, surgery and neurological or other complex conditions. Services have been delivered through dedicated rehabilitation centres and rehabilitation units within general hospitals, with facilities located across several Australian states and territories.

• Disability and community support

  Healthscope Independence Services

  Healthscope Independence Services has provided accommodation, attendant care, transitional support, respite and in-home services for people with acquired brain injuries, disabilities, complex conditions and those requiring assistance after leaving hospital. Its geographic coverage has included metropolitan and regional areas in Victoria, New South Wales and the Northern Territory.

• Medical diagnostics

  Pathology services

  Pathology was historically an important part of Healthscope's healthcare portfolio in Australia and New Zealand. The Australian business was sold to Crescent Capital Partners in 2015, while the New Zealand pathology business was sold to NZ Super in 2020.

• Primary and specialist care

  Medical centres

  Healthscope formerly operated a portfolio of medical centres and specialist clinics, including skin clinics and a breast diagnostic clinic. The division was sold to Fullerton Healthcare in 2017 as the group concentrated more heavily on hospitals and specialist inpatient care.

• 2025

  Receivership and administrationOther

  Background

  Lenders withdrew support for Brookfield-owned Healthscope amid reported debt of approximately A$1.6 billion and concerns about the company's ability to continue funding its facilities.

  Action taken

  McGrathNicol was appointed receiver and manager, KordaMentha was appointed administrator, and Commonwealth Bank provided an additional A$100 million to support ongoing operations.

  Aftermath

  The hospital network continued operating while receivers and administrators assessed the company's ownership, financing and future asset structure.

  Reported debt. A$1.6 billion (2025)

  Source

• 2019

  Acquisition by Brookfield Business PartnersM&A

  Background

  Brookfield Business Partners pursued a takeover of Healthscope with institutional investment partners.

  Action taken

  Brookfield completed the acquisition on 6 June 2019, with the Caisse de dépôt et placement du Québec retaining a minority stake.

  Aftermath

  Healthscope was delisted and continued as a privately owned hospital operator.

  Source

• 2017

  Sale of medical-centre portfolioM&A

  Background

  The group continued to focus its portfolio on hospitals and specialist hospital services.

  Action taken

  Healthscope sold its medical-centre division and associated specialist clinics to Fullerton Healthcare.

  Aftermath

  The transaction reduced Healthscope's exposure to primary-care and outpatient clinic operations.

  Source

• 2015

  Sale of Australian PathologyM&A

  Background

  Healthscope reviewed its portfolio of healthcare businesses and separated its Australian pathology operations from its hospital-focused activities.

  Action taken

  The Australian Pathology division was sold to Crescent Capital Partners.

  Aftermath

  Pathology ceased to be part of Healthscope's Australian operating portfolio.

  Source

• 2014

  Relisting on the Australian Securities ExchangeOther

  Background

  After several years under private ownership, Healthscope pursued a return to public markets.

  Action taken

  The company was relisted on 28 July 2014 and later traded under the code HSO.

  Aftermath

  Healthscope re-entered the S&P/ASX 200 Index before being acquired and delisted again in 2019.

  Source

• 2010

  Acquisition by TPG Capital and The Carlyle GroupM&A

  Background

  Healthscope was acquired by a consortium advised and managed by TPG Capital and The Carlyle Group after its first period as an ASX-listed company.

  Action taken

  The consortium took the company private and Healthscope was removed from the ASX.

  Aftermath

  The business continued under private ownership before returning to the public market in 2014.

  Source

• 2020.08.06

  Healthscope agrees to sell its New Zealand pathology business[2]Healthscope同意出售其新西兰病理业务scoop.co.nz

  Healthscope agreed to sell its New Zealand pathology business, Asia Pacific Healthcare Group, to the New Zealand Superannuation Fund and Ontario Teachers' Pension Plan, which would each take a 50% share. The sale is subject to customary approvals, with completion expected within six months.

Read more

1. 1Healthscopeen.wikipedia.org
2. 2Healthscope同意出售其新西兰病理业务scoop.co.nz